Strain Name:

(C57BL/6-Tg(TRAMP)8247Ng/J X FVB/NJ)F1/J

Stock Number:

008215

Availability:

Repository- Live

Use Restrictions Apply, see Purchasing Information
These mice express the TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) transgene and develop progressive forms of prostate cancer with distant site metastasis. An earlier onset of the phenotype is observed in these F1 background mice when compared to mice carrying the transgene on the C57BL/6 background.

Description

Strain Information

Type Transgenic;
Type *F1 Hybrid;
Additional information on Hybrid Strains.
Mating SystemHemizygote x Inbred         (Female x Male)
Specieslaboratory mouse
 
Donating Investigator IMR Colony,   The Jackson Laboratory

Description
Mice carrying the TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) transgene develop progressive forms of prostate cancer with distant site metastasis, primarily to the lymph nodes and lungs. These transgenic mice express the simian virus 40 (SV40) large tumor T antigen (Tag) under the control of the rat probasin promoter. Expression of the transgene is specific to the prostate epithelium. Transgenic mice exhibit various forms of disease from mild intraepithelial hyperplasia to large multinodular malignant neoplasia. The median survival time for these F1 transgenic mice is 19 weeks, very few mice survive past 33 weeks of age, which is significantly shorter than the lifespan of transgenic mice on the C57BL/6 background. Comparative histological analysis of tumors from these F1 transgenic mice and from transgenic mice on the C57BL/6 background reveals that the tumors found in these F1 mutants arise from the dorsolateral and ventral lobes of the prostate and are more spherical, highly vascularized masses. The tumors found in the C57BL/6 background transgenic mice arise from the prostate lateral lobes and often invade the surrounding tissues (urethra and seminal vesicles).

Development
The TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) transgenic construct, containing the simian virus 40 (SV40) large tumor T antigen (Tag) under the control of the rat probasin promoter, was injected into fertilized C57BL/6 mouse eggs. Founder line 8247 was established. To generate this F1 strain, TRAMP transgenic females (Stock No. 003135) are mated with FVB/NJ males (Stock No. 001800).

Control Information

  Control
   Noncarrier
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Tg(TRAMP)8247Ng allele
003135   C57BL/6-Tg(TRAMP)8247Ng/J
View Strains carrying   Tg(TRAMP)8247Ng     (1 strain)

View Strains carrying other alleles of TAg     (12 strains)

Phenotype

Phenotype Information

Related Disease (OMIM) Terms

Prostate Cancer

Mammalian Phenotype Terms assigned by genotype

The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.

Tg(TRAMP)8247Ng/0

        involves: 129S1/Sv * C57BL/6
  • tumorigenesis
  • prostate tumor (MGI Ref ID J:108849)

Tg(TRAMP)8247Ng/0

        involves: C57BL/6
  • tumorigenesis
  • prostate tumor (MGI Ref ID J:65303)
    • males display focal and invasive adenocarcinoma of the prostate by 20 weeks
  • reproductive system phenotype
  • prostate gland hyperplasia (MGI Ref ID J:65303)
    • intraepithelial hyperplasia can be detected in males by 10 weeks of age and by 22 weeks of age, almost all prostatic glands are hyperplastic
  • endocrine/exocrine gland phenotype
  • prostate gland hyperplasia (MGI Ref ID J:65303)
    • intraepithelial hyperplasia can be detected in males by 10 weeks of age and by 22 weeks of age, almost all prostatic glands are hyperplastic

Tg(TRAMP)8247Ng/0

        involves: C3H * C57BL/6
  • endocrine/exocrine gland phenotype
  • increased prostate weight (MGI Ref ID J:125633)
    • prostates weigh an average of >6g, while in transgenic mice expressing the Tg(ACTB-SAC/EGFP)35Rang transgene, most (78.5%) prostate glands weigh <2g and remaining 21.5% weigh between 2 and 3 grams
  • reproductive system phenotype
  • increased prostate weight (MGI Ref ID J:125633)
    • prostates weigh an average of >6g, while in transgenic mice expressing the Tg(ACTB-SAC/EGFP)35Rang transgene, most (78.5%) prostate glands weigh <2g and remaining 21.5% weigh between 2 and 3 grams
  • tumorigenesis
  • prostate tumor (MGI Ref ID J:125633)
    • majority (62.5-83.3%) of mice develop high-grade prostatic intraepithelial neoplasia by 3 months of age and 12-16% of animals show adenocarcinoma of the prostate; by 6 months, all mice develop adenocarcinoma of the prostate

Research Applications

This mouse can be used to support research in many areas including:

Apoptosis Research
Extracellular Modulators

Cancer Research
Increased Tumor Incidence (Prostate Tumors)
Other (tumor metastasis)

Reproductive Biology Research
Prostate Tumors

Research Tools
Cancer Research (tumor immunology)

TAg related

Apoptosis Research
Extracellular Modulators

Genes & Alleles

Gene & Allele Information

Allele Symbol Tg(TRAMP)8247Ng
Allele Name transgene insertion 8247, Norman M Greenberg
Common Name(s) TRAMP;
Mutation Made By Norman Greenberg,   Fred Hutchinson Cancer Research Center
Strain of OriginC57BL/6
Expressed Gene TAg, SV40 large T-antigen, SV40
Simian virus 40 T antigen (SV40Tag) is a multifunctional regulatory protein that stimulates gene transcription and forms complexes with cell cycle-regulatory proteins such as Trp53 and Rb1 that are implicated in human breast cancer.
Promoter Pb, probasin, rat
General Note TRAMP stands for TRansgenic Adenocarcinoma Mouse Prostate. Lines 5666 and 8079 were also produced.

Transgenic mice on a C57BL6 background develop progressive forms of prostate cancer with distant site metastasis. Forms ofdisease range from mild intraepithelial hyperplasia to large multinodular malignant neoplasia. Tumors are detected in the prostate as early as 10 weeks of age. The tumors have elevated levels of nuclear TRP53 and decreased androgen receptor expression.

Molecular Note Expression of the SV40 early region tumor antigen was driven in mouse prostrate epithelium via a rat probasin promoter region fragment (-426/+28 bp). [MGI Ref ID J:65303] [MGI Ref ID J:73560]

Genotyping

Genotyping Information

Genotyping Protocols

Tg(TRAMP)8247Ng, SEP PCR, vers. 1

Helpful Links

Optimizing PCR Protocols

References

References

Selected Reference(s)

Greenberg NM; DeMayo F; Finegold MJ; Medina D; Tilley WD; Aspinall JO; Cunha GR; Donjacour AA; Matusik RJ; Rosen JM. 1995. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92(8):3439-43. [PubMed: 7724580]  [MGI Ref ID J:65303]

Additional References

Tg(TRAMP)8247Ng related

Abdulkadir SA; Qu Z; Garabedian E; Song SK; Peters TJ; Svaren J; Carbone JM; Naughton CK; Catalona WJ; Ackerman JJ; Gordon JI; Humphrey PA; Milbrandt J. 2001. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 7(1):101-7. [PubMed: 11135623]  [MGI Ref ID J:67125]

Adhami VM; Siddiqui IA; Ahmad N; Gupta S; Mukhtar H. 2004. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 64(23):8715-22. [PubMed: 15574782]  [MGI Ref ID J:94677]

Albertelli MA; O'Mahony OA; Brogley M; Tosoian J; Steinkamp M; Daignault S; Wojno K; Robins DM. 2008. Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice. Hum Mol Genet 17(1):98-110. [PubMed: 17906287]  [MGI Ref ID J:132039]

Albertelli MA; Scheller A; Brogley M; Robins DM. 2006. Replacing the mouse androgen receptor with human alleles demonstrates glutamine tract length-dependent effects on physiology and tumorigenesis in mice. Mol Endocrinol 20(6):1248-60. [PubMed: 16601069]  [MGI Ref ID J:108849]

Anzo M; Cobb LJ; Hwang DL; Mehta H; Said JW; Yakar S; LeRoith D; Cohen P. 2008. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res 68(9):3342-9. [PubMed: 18451161]  [MGI Ref ID J:134610]

Azzali G. 2007. Tumor cell transendothelial passage in the absorbing lymphatic vessel of transgenic adenocarcinoma mouse prostate. Am J Pathol 170(1):334-46. [PubMed: 17200205]  [MGI Ref ID J:117198]

Bao Y; Peng W; Verbitsky A; Chen J; Wu L; Rauen KA; Sawicki JA. 2005. Human coxsackie adenovirus receptor (CAR) expression in transgenic mouse prostate tumors enhances adenoviral delivery of genes. Prostate 64(4):401-7. [PubMed: 15761871]  [MGI Ref ID J:100079]

Bok RA; Hansell EJ; Nguyen TP; Greenberg NM; McKerrow JH; Shuman MA. 2003. Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model. Prostate Cancer Prostatic Dis 6(4):272-80. [PubMed: 14663466]  [MGI Ref ID J:100578]

Bradley SV; Oravecz-Wilson KI; Bougeard G; Mizukami I; Li L; Munaco AJ; Sreekumar A; Corradetti MN; Chinnaiyan AM; Sanda MG; Ross TS. 2005. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res 65(10):4126-33. [PubMed: 15899803]  [MGI Ref ID J:98551]

Bruckheimer EM; Brisbay S; Johnson DJ; Gingrich JR; Greenberg N; McDonnell TJ. 2000. Bcl-2 accelerates multistep prostate carcinogenesis in vivo Oncogene 19(46):5251-8. [PubMed: 11077442]  [MGI Ref ID J:65876]

Caporali A; Davalli P; Astancolle S; D'Arca D; Brausi M; Bettuzzi S; Corti A. 2004. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 25(11):2217-24. [PubMed: 15358631]  [MGI Ref ID J:93777]

Chiaverotti T; Couto SS; Donjacour A; Mao JH; Nagase H; Cardiff RD; Cunha GR; Balmain A. 2008. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 172(1):236-46. [PubMed: 18156212]  [MGI Ref ID J:130924]

Chung AC; Zhou S; Liao L; Tien JC; Greenberg NM; Xu J. 2007. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Cancer Res 67(12):5965-75. [PubMed: 17575167]  [MGI Ref ID J:122392]

Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M. 2008. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res 68(1):292-300. [PubMed: 18172322]  [MGI Ref ID J:131032]

Degl'innocenti E; Grioni M; Boni A; Camporeale A; Bertilaccio MT; Freschi M; Monno A; Arcelloni C; Greenberg NM; Bellone M. 2004. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 35(1):66-75. [PubMed: 15597325]  [MGI Ref ID J:95463]

Drake CG; Doody AD; Mihalyo MA; Huang CT; Kelleher E; Ravi S; Hipkiss EL; Flies DB; Kennedy EP; Long M; McGary PW; Coryell L; Nelson WG; Pardoll DM; Adler AJ. 2005. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7(3):239-49. [PubMed: 15766662]  [MGI Ref ID J:96922]

Dubey P; Wu H; Reiter RE; Witte ON. 2001. Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. Cancer Res 61(8):3256-61. [PubMed: 11309275]  [MGI Ref ID J:69227]

Ende N; Chen R; Reddi AS. 2006. Administration of human umbilical cord blood cells delays the onset of prostate cancer and increases the lifespan of the TRAMP mouse. Cancer Lett 231(1):123-8. [PubMed: 16356837]  [MGI Ref ID J:104030]

Eng MH; Charles LG; Ross BD; Chrisp CE; Pienta KJ; Greenberg NM; Hsu CX; Sanda MG. 1999. Early castration reduces prostatic carcinogenesis in transgenic mice Urology 54(6):1112-9. [PubMed: 10604719]  [MGI Ref ID J:59577]

Feng S; Agoulnik IU; Bogatcheva NV; Kamat AA; Kwabi-Addo B; Li R; Ayala G; Ittmann MM; Agoulnik AI. 2007. Relaxin promotes prostate cancer progression. Clin Cancer Res 13(6):1695-702. [PubMed: 17363522]  [MGI Ref ID J:122670]

Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM. 1997. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57(16):3325-30. [PubMed: 9269988]  [MGI Ref ID J:42333]

Foster BA; Kaplan PJ; Greenberg NM. 1999. Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model. Prostate Cancer Prostatic Dis 2(2):76-82. [PubMed: 12496842]  [MGI Ref ID J:84412]

Fricke ST; Rodriguez O; Vanmeter J; Dettin LE; Casimiro M; Chien CD; Newell T; Johnson K; Ileva L; Ojeifo J; Johnson MD; Albanese C. 2006. In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate cancer models. Prostate 66(7):708-17. [PubMed: 16425198]  [MGI Ref ID J:110412]

Fritz WA; Lin TM; Peterson RE. 2008. The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates. Carcinogenesis 29(5):1077-82. [PubMed: 18359762]  [MGI Ref ID J:138497]

Garcia GE; Wisniewski HG; Lucia MS; Arevalo N; Slaga TJ; Kraft SL; Strange R; Kumar AP. 2006. 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6. Clin Cancer Res 12(3 Pt 1):980-8. [PubMed: 16467113]  [MGI Ref ID J:107341]

Gingrich JR; Barrios RJ; Foster BA; Greenberg NM. 1999. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 2(2):70-75. [PubMed: 12496841]  [MGI Ref ID J:66957]

Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM. 1997. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57(21):4687-91. [PubMed: 9354422]  [MGI Ref ID J:65305]

Gingrich JR; Barrios RJ; Morton RA; Boyce BF; DeMayo FJ; Finegold MJ; Angelopoulou R; Rosen JM; Greenberg NM. 1996. Metastatic prostate cancer in a transgenic mouse. Cancer Res 56(18):4096-102. [PubMed: 8797572]  [MGI Ref ID J:65304]

Glinsky GV; Berezovska O; Glinskii AB. 2005. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115(6):1503-21. [PubMed: 15931389]  [MGI Ref ID J:99201]

Goel HL; Breen M; Zhang J; Das I; Aznavoorian-Cheshire S; Greenberg NM; Elgavish A; Languino LR. 2005. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Res 65(15):6692-700. [PubMed: 16061650]  [MGI Ref ID J:100772]

Graves CW; Philips ST; Bradley SV; Oravecz-Wilson KI; Li L; Gauvin A; Ross TS. 2008. Use of a cryptic splice site for the expression of huntingtin interacting protein 1 in select normal and neoplastic tissues. Cancer Res 68(4):1064-73. [PubMed: 18281481]  [MGI Ref ID J:131697]

Greenberg NM. 2000. Androgens and growth factors in prostate cancer: a transgenic perspective. Prostate Cancer Prostatic Dis 3(4):224-228. [PubMed: 12497068]  [MGI Ref ID J:81103]

Grossmann ME; Davila T; Celis T. 2001. Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother 24(3):237-41. [PubMed: 11394501]  [MGI Ref ID J:69753]

Grosso JF; Kelleher CC; Harris TJ; Maris CH; Hipkiss EL; De Marzo A; Anders R; Netto G; Getnet D; Bruno TC; Goldberg MV; Pardoll DM; Drake CG. 2007. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 117(11):3383-92. [PubMed: 17932562]  [MGI Ref ID J:127434]

Guerra N; Tan YX; Joncker NT; Choy A; Gallardo F; Xiong N; Knoblaugh S; Cado D; Greenberg NR; Raulet DH. 2008. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28(4):571-80. [PubMed: 18394936]  [MGI Ref ID J:134509]

Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H. 2004. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64(9):3334-43. [PubMed: 15126378]  [MGI Ref ID J:89552]

Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H. 2000. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res 60(18):5125-33. [PubMed: 11016639]  [MGI Ref ID J:64783]

Gupta S; Hastak K; Ahmad N; Lewin JS; Mukhtar H. 2001. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 98(18):10350-5. [PubMed: 11504910]  [MGI Ref ID J:70896]

Han G; Foster BA; Mistry S; Buchanan G; Harris JM; Tilley WD; Greenberg NM. 2001. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 276(14):11204-13. [PubMed: 11063747]  [MGI Ref ID J:69752]

Hernandez I; Maddison LA; Wei Y; DeMayo F; Petras T; Li B; Gingrich JR; Rosen JM; Greenberg NM. 2003. Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. Mol Cancer Res 1(14):1036-47. [PubMed: 14707287]  [MGI Ref ID J:87255]

Hill RE; De Avila DM; Bertrand KP; Greenberg NM; Reeves JJ. 2003. Immunization against luteinizing hormone-releasing hormone fusion proteins does not decrease prostate cancer in the transgenic adenocarcinoma mouse prostate model. Exp Biol Med (Maywood) 228(7):818-22. [PubMed: 12876301]  [MGI Ref ID J:85008]

Hooker AM; Morley AA; Tilley WD; Sykes PJ. 2004. Cancer-associated genes can affect somatic intrachromosomal recombination early in carcinogenesis. Mutat Res 550(1-2):1-10. [PubMed: 15135636]  [MGI Ref ID J:90162]

Hsu CX; Ross BD; Chrisp CE; Derrow SZ; Charles LG; Pienta KJ; Greenberg NM; Zeng Z; Sanda MG. 1998. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urol 160(4):1500-5. [PubMed: 9751403]  [MGI Ref ID J:50294]

Huffman DM; Grizzle WE; Bamman MM; Kim JS; Eltoum IA; Elgavish A; Nagy TR. 2007. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67(14):6612-8. [PubMed: 17638871]  [MGI Ref ID J:123143]

Huffman DM; Johnson MS; Watts A; Elgavish A; Eltoum IA; Nagy TR. 2007. Cancer progression in the transgenic adenocarcinoma of mouse prostate mouse is related to energy balance, body mass, and body composition, but not food intake. Cancer Res 67(1):417-24. [PubMed: 17185379]  [MGI Ref ID J:117224]

Hurwitz AA; Foster BA; Kwon ED; Truong T; Choi EM; Greenberg NM; Burg MB; Allison JP. 2000. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60(9):2444-8. [PubMed: 10811122]  [MGI Ref ID J:62479]

Huss WJ; Barrios RJ; Foster BA; Greenberg NM. 2003. Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 54(1):8-16. [PubMed: 12481250]  [MGI Ref ID J:81095]

Huss WJ; Barrios RJ; Greenberg NM. 2003. SU5416 Selectively Impairs Angiogenesis to Induce Prostate Cancer-specific Apoptosis. Mol Cancer Ther 2(7):611-6. [PubMed: 12883033]  [MGI Ref ID J:85002]

Huss WJ; Gray DR; Greenberg NM; Mohler JL; Smith GJ. 2005. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res 65(15):6640-50. [PubMed: 16061644]  [MGI Ref ID J:100779]

Huss WJ; Gray DR; Tavakoli K; Marmillion ME; Durham LE; Johnson MA; Greenberg NM; Smith GJ. 2007. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 9(11):938-50. [PubMed: 18030362]  [MGI Ref ID J:131744]

Huss WJ; Hanrahan CF; Barrios RJ; Simons JW; Greenberg NM. 2001. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61(6):2736-43. [PubMed: 11289156]  [MGI Ref ID J:68468]

Iordanescu I; Becker C; Zetter B; Dunning P; Taylor GA. 2002. Tumor vascularity: evaluation in a murine model with contrast-enhanced color Doppler US effect of angiogenesis inhibitors. Radiology 222(2):460-7. [PubMed: 11818614]  [MGI Ref ID J:74408]

Ishii K; Shappell SB; Matusik RJ; Hayward SW. 2005. Use of tissue recombination to predict phenotypes of transgenic mouse models of prostate carcinoma. Lab Invest 85(9):1086-103. [PubMed: 15980886]  [MGI Ref ID J:100901]

Johnson MA; Hernandez I; Wei Y; Greenberg N. 2000. Isolation and characterization of mouse probasin: An androgen-regulated protein specifically expressed in the differentiated prostate Prostate 43(4):255-62. [PubMed: 10861744]  [MGI Ref ID J:62973]

Kalin TV; Wang IC; Ackerson TJ; Major ML; Detrisac CJ; Kalinichenko VV; Lyubimov A; Costa RH. 2006. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 66(3):1712-20. [PubMed: 16452231]  [MGI Ref ID J:106668]

Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM. 1999. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 59(9):2203-9. [PubMed: 10232609]  [MGI Ref ID J:54539]

Kaplan-Lefko PJ; Chen TM; Ittmann MM; Barrios RJ; Ayala GE; Huss WJ; Maddison LA; Foster BA; Greenberg NM. 2003. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55(3):219-37. [PubMed: 12692788]  [MGI Ref ID J:83083]

Kee K; Foster BA; Merali S; Kramer DL; Hensen ML; Diegelman P; Kisiel N; Vujcic S; Mazurchuk RV; Porter CW. 2004. Activated polyamine catabolism depletes acetyl-CoA pools and suppresses prostate tumor growth in TRAMP mice. J Biol Chem 279(38):40076-83. [PubMed: 15252047]  [MGI Ref ID J:93350]

Kelavkar UP; Glasgow W; Olson SJ; Foster BA; Shappell SB. 2004. Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice. Neoplasia 6(6):821-30. [PubMed: 15720809]  [MGI Ref ID J:97875]

Klein RD. 2005. The use of genetically engineered mouse models of prostate cancer for nutrition and cancer chemoprevention research. Mutat Res 576(1-2):111-9. [PubMed: 15885713]  [MGI Ref ID J:100619]

Klezovitch O; Risk M; Coleman I; Lucas JM; Null M; True LD; Nelson PS; Vasioukhin V. 2008. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 105(6):2105-10. [PubMed: 18245377]  [MGI Ref ID J:131932]

Kwabi-Addo B; Giri D; Schmidt K; Podsypanina K; Parsons R; Greenberg N; Ittmann M. 2001. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A 98(20):11563-8. [PubMed: 11553783]  [MGI Ref ID J:71740]

Kwon ED; Foster BA; Hurwitz AA; Madias C; Allison JP; Greenberg NM; Burg MB. 1999. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy Proc Natl Acad Sci U S A 96(26):15074-9. [PubMed: 10611340]  [MGI Ref ID J:59573]

Le Dur A; Beringue V; Andreoletti O; Reine F; Lai TL; Baron T; Bratberg B; Vilotte JL; Sarradin P; Benestad SL; Laude H. 2005. A newly identified type of scrapie agent can naturally infect sheep with resistant PrP genotypes. Proc Natl Acad Sci U S A 102(44):16031-6. [PubMed: 16239348]  [MGI Ref ID J:102929]

Leman ES; Arlotti JA; Dhir R; Greenberg N; Getzenberg RH. 2002. Characterization of the nuclear matrix proteins in a transgenic mouse model for prostate cancer. J Cell Biochem 86(2):203-12. [PubMed: 12111990]  [MGI Ref ID J:77969]

Li H; Gerald WL; Benezra R. 2004. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res 64(17):6137-43. [PubMed: 15342397]  [MGI Ref ID J:92409]

Lin X; Gingrich JR; Bao W; Li J; Haroon ZA; Demark-Wahnefried W. 2002. Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice. Urology 60(5):919-24. [PubMed: 12429338]  [MGI Ref ID J:80307]

Luo JL; Tan W; Ricono JM; Korchynskyi O; Zhang M; Gonias SL; Cheresh DA; Karin M. 2007. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446(7136):690-4. [PubMed: 17377533]  [MGI Ref ID J:121432]

Majeed N; Blouin MJ; Kaplan-Lefko PJ; Barry-Shaw J; Greenberg NM; Gaudreau P; Bismar TA; Pollak M. 2005. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 24(29):4736-40. [PubMed: 15870705]  [MGI Ref ID J:99544]

Martiniello-Wilks R; Dane A; Mortensen E; Jeyakumar G; Wang XY; Russell PJ. 2003. Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies. Anticancer Res 23(3B):2633-42. [PubMed: 12894551]  [MGI Ref ID J:84993]

McCabe MT; Low JA; Daignault S; Imperiale MJ; Wojno KJ; Day ML. 2006. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 66(1):385-92. [PubMed: 16397253]  [MGI Ref ID J:105165]

Mentor-Marcel R; Lamartiniere CA; Eltoum IA; Greenberg NM; Elgavish A. 2005. Dietary Genistein Improves Survival and Reduces Expression of Osteopontin in the Prostate of Transgenic Mice with Prostatic Adenocarcinoma (TRAMP). J Nutr 135(5):989-95. [PubMed: 15867270]  [MGI Ref ID J:98642]

Mentor-Marcel R; Lamartiniere CA; Eltoum IE; Greenberg NM; Elgavish A. 2001. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 61(18):6777-82. [PubMed: 11559550]  [MGI Ref ID J:71655]

Moghaddami M; Swart B; Reynolds P; Diener K; Brown MP. 2002. Flt3 ligand expands dendritic cell numbers in normal and malignant murineprostate. Immunol Cell Biol 80(4):370-81. [PubMed: 12121227]  [MGI Ref ID J:77987]

Moore ML; Teitell MA; Kim Y; Watabe T; Reiter RE; Witte ON; Dubey P. 2008. Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate 68(2):139-51. [PubMed: 18044730]  [MGI Ref ID J:133908]

Morey SR; Smiraglia DJ; James SR; Yu J; Moser MT; Foster BA; Karpf AR. 2006. DNA methylation pathway alterations in an autochthonous murine model of prostate cancer. Cancer Res 66(24):11659-67. [PubMed: 17178860]  [MGI Ref ID J:116759]

Naff KA; Van Pelt C; Craig S; Gray K. 2005. Perianal mass in a female transgenic mouse. Lab Anim (NY) 34(4):31, 32-3. [PubMed: 15806087]  [MGI Ref ID J:101145]

Nanda NK; Birch L; Greenberg NM; Prins GS. 2006. MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment. Prostate 66(12):1275-84. [PubMed: 16741922]  [MGI Ref ID J:115823]

Narayanan BA; Narayanan NK; Pittman B; Reddy BS. 2004. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 10(22):7727-37. [PubMed: 15570007]  [MGI Ref ID J:95483]

Narayanan BA; Narayanan NK; Pttman B; Reddy BS. 2006. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. Prostate 66(3):257-65. [PubMed: 16175586]  [MGI Ref ID J:107090]

Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM. 2005. Versatile prostate cancer treatment with inducible caspase and interleukin-12. Cancer Res 65(10):4309-19. [PubMed: 15899823]  [MGI Ref ID J:98548]

Ozawa MG; Yao VJ; Chanthery YH; Troncoso P; Uemura A; Varner AS; Kasman IM; Pasqualini R; Arap W; McDonald DM. 2005. Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma. Cancer 104(10):2104-15. [PubMed: 16208706]  [MGI Ref ID J:103697]

Peng SL; Townsend MJ; Hecht JL; White IA; Glimcher LH. 2004. T-bet regulates metastasis rate in a murine model of primary prostate cancer. Cancer Res 64(2):452-5. [PubMed: 14744755]  [MGI Ref ID J:88093]

Phelps CJ. 1994. Pituitary hormones as neurotrophic signals: anomalous hypophysiotrophic neuron differentiation in hypopituitary dwarf mice. Proc Soc Exp Biol Med 206(1):6-23. [PubMed: 7910409]  [MGI Ref ID J:18152]

Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M. 2003. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 63(18):5754-60. [PubMed: 14522896]  [MGI Ref ID J:86075]

Pu YS; Luo W; Lu HH; Greenberg NM; Lin SH; Gingrich JR. 1999. Differential expression of C-CAM cell adhesion molecule in prostate carcinogenesis in a transgenic mouse model [published erratum appears in J Urol 2000 Jan;163(1):253] J Urol 162(3 Pt 1):892-6. [PubMed: 10458403]  [MGI Ref ID J:57429]

Raghow S; Hooshdaran MZ; Katiyar S; Steiner MS. 2002. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62(5):1370-6. [PubMed: 11888907]  [MGI Ref ID J:75227]

Raghow S; Kuliyev E; Steakley M; Greenberg N; Steiner MS. 2000. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. Cancer Res 60(15):4093-7. [PubMed: 10945615]  [MGI Ref ID J:64630]

Raina K; Rajamanickam S; Singh RP; Deep G; Chittezhath M; Agarwal R. 2008. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 68(16):6822-30. [PubMed: 18701508]  [MGI Ref ID J:139140]

Rao DS; Hyun TS; Kumar PD; Mizukami IF; Rubin MA; Lucas PC; Sanda MG; Ross TS. 2002. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest 110(3):351-60. [PubMed: 12163454]  [MGI Ref ID J:78515]

Robins DM; Albertelli MA; O'Mahony OA. 2008. Androgen receptor variants and prostate cancer in humanized AR mice. J Steroid Biochem Mol Biol 108(3-5):230-6. [PubMed: 17936615]  [MGI Ref ID J:131199]

Saez E; Olson P; Evans RM. 2003. Genetic deficiency in Pparg does not alter development of experimental prostate cancer. Nat Med 9(10):1265-1266. [PubMed: 12960963]  [MGI Ref ID J:86096]

Saleem M; Adhami VM; Ahmad N; Gupta S; Mukhtar H. 2005. Prognostic Significance of Metastasis-Associated Protein S100A4 (Mts1) in Prostate Cancer Progression and Chemoprevention Regimens in an Autochthonous Mouse Model. Clin Cancer Res 11(1):147-53. [PubMed: 15671539]  [MGI Ref ID J:96273]

Savage PA; Vosseller K; Kang C; Larimore K; Riedel E; Wojnoonski K; Jungbluth AA; Allison JP. 2008. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 319(5860):215-20. [PubMed: 18187659]  [MGI Ref ID J:131347]

Schatten H; Wiedemeier AM; Taylor M; Lubahn DB; Greenberg NM; Besch-Williford C; Rosenfeld CS; Day JK; Ripple M. 2000. Centrosome-centriole abnormalities are markers for abnormal cell divisions and cancer in the transgenic adenocarcinoma mouse prostate (TRAMP) model. Biol Cell 92(5):331-40. [PubMed: 11071042]  [MGI Ref ID J:65344]

Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW. 2003. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model. Prostate 55(4):308-16. [PubMed: 12712410]  [MGI Ref ID J:83064]

Shen H; Schuster R; Lu B; Waltz SE; Lentsch AB. 2006. Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate 66(16):1721-8. [PubMed: 16941672]  [MGI Ref ID J:115957]

Shen H; Schuster R; Stringer KF; Waltz SE; Lentsch AB. 2006. The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J 20(1):59-64. [PubMed: 16394268]  [MGI Ref ID J:104574]

Shepard CR; Kassis J; Whaley DL; Kim HG; Wells A. 2007. PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene 26(21):3020-6. [PubMed: 17130835]  [MGI Ref ID J:122884]

Shih SC; Robinson GS; Perruzzi CA; Calvo A; Desai K; Green JE; Ali IU; Smith LE; Senger DR. 2002. Molecular profiling of angiogenesis markers. Am J Pathol 161(1):35-41. [PubMed: 12107087]  [MGI Ref ID J:77978]

Shukla S; MacLennan GT; Flask CA; Fu P; Mishra A; Resnick MI; Gupta S. 2007. Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res 67(14):6925-35. [PubMed: 17638904]  [MGI Ref ID J:123137]

Siddiqui IA; Shukla Y; Adhami VM; Sarfaraz S; Asim M; Hafeez BB; Mukhtar H. 2008. Suppression of NFkappaB and its Regulated Gene Products by Oral Administration of Green Tea Polyphenols in an Autochthonous Mouse Prostate Cancer Model. Pharm Res 25(9):2135-42. [PubMed: 18317887]  [MGI Ref ID J:138094]

Sutherland BW; Knoblaugh SE; Kaplan-Lefko PJ; Wang F; Holzenberger M; Greenberg NM. 2008. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res 68(9):3495-504. [PubMed: 18451178]  [MGI Ref ID J:134608]

Suttie A; Nyska A; Haseman JK; Moser GJ; Hackett TR; Goldsworthy TL. 2003. A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model. Toxicol Pathol 31(1):31-8. [PubMed: 12597447]  [MGI Ref ID J:81938]

Suttie AW; Dinse GE; Nyska A; Moser GJ; Goldsworthy TL; Maronpot RR. 2005. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse. Toxicol Pathol 33(3):386-97. [PubMed: 15805078]  [MGI Ref ID J:97938]

Tam NN; Nyska A; Maronpot RR; Kissling G; Lomnitski L; Suttie A; Bakshi S; Bergman M; Grossman S; Ho SM. 2006. Differential attenuation of oxidative/nitrosative injuries in early prostatic neoplastic lesions in TRAMP mice by dietary antioxidants. Prostate 66(1):57-69. [PubMed: 16114064]  [MGI Ref ID J:107353]

Tani Y; Suttie A; Flake GP; Nyska A; Maronpot RR. 2005. Epithelial-stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model. Vet Pathol 42(3):306-14. [PubMed: 15872376]  [MGI Ref ID J:101136]

Wadsworth TL; Worstell TR; Greenberg NM; Roselli CE. 2007. Effects of dietary saw palmetto on the prostate of transgenic adenocarcinoma of the mouse prostate model (TRAMP). Prostate 67(6):661-73. [PubMed: 17342743]  [MGI Ref ID J:122650]

Wang X; Colby JK; Yang P; Fischer SM; Newman RA; Klein RD. 2008. The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue. Carcinogenesis 29(1):120-8. [PubMed: 17942462]  [MGI Ref ID J:131198]

Watabe T; Lin M; Ide H; Donjacour AA; Cunha GR; Witte ON; Reiter RE. 2002. Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proc Natl Acad Sci U S A 99(1):401-6. [PubMed: 11752398]  [MGI Ref ID J:73560]

Wechter WJ; Leipold DD; Murray ED Jr; Quiggle D; McCracken JD; Barrios RS; Greenberg NM. 2000. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse Cancer Res 60(8):2203-8. [PubMed: 10786685]  [MGI Ref ID J:61729]

Wikstrom P; Bylund A; Zhang JX; Hallmans G; Stattin P; Bergh A. 2005. Rye bran diet increases epithelial cell apoptosis and decreases epithelial cell volume in TRAMP (transgenic adenocarcinoma of the mouse prostate) tumors. Nutr Cancer 53(1):111-6. [PubMed: 16351513]  [MGI Ref ID J:106944]

Williams TM; Hassan GS; Li J; Cohen AW; Medina F; Frank PG; Pestell RG; Di Vizio D; Loda M; Lisanti MP. 2005. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem 280(26):25134-45. [PubMed: 15802273]  [MGI Ref ID J:133066]

Wong SY; Crowley D; Bronson RT; Hynes RO. 2008. Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clin Exp Metastasis 25(2):109-18. [PubMed: 18058030]  [MGI Ref ID J:133592]

Wood RW; Baggs RB; Schwarz EM; Messing EM. 2006. Initial observations of reduced uroflow in transgenic adenocarcinoma of murine prostate. Urology 67(6):1324-8. [PubMed: 16765198]  [MGI Ref ID J:115829]

Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW. 2005. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model. J Urol 173(5):1778-83. [PubMed: 15821586]  [MGI Ref ID J:98661]

Xuan JW; Bygrave M; Jiang H; Valiyeva F; Dunmore-Buyze J; Holdsworth DW; Izawa JI; Bauman G; Moussa M; Winter SF; Greenberg NM; Chin JL; Drangova M; Fenster A; Lacefield JC. 2007. Functional neoangiogenesis imaging of genetically engineered mouse prostate cancer using three-dimensional power Doppler ultrasound. Cancer Res 67(6):2830-9. [PubMed: 17363606]  [MGI Ref ID J:120312]

Zhao Y; Burikhanov R; Qiu S; Lele SM; Jennings CD; Bondada S; Spear B; Rangnekar VM. 2007. Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res 67(19):9276-85. [PubMed: 17909035]  [MGI Ref ID J:125633]

Zheng X; Gao JX; Zhang H; Geiger TL; Liu Y; Zheng P. 2002. Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors. J Immunol 169(9):4761-9. [PubMed: 12391185]  [MGI Ref ID J:132836]

Zorn CS; Wojno KJ; McCabe MT; Kuefer R; Gschwend JE; Day ML. 2007. 5-aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin Cancer Res 13(7):2136-43. [PubMed: 17404097]  [MGI Ref ID J:123845]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX12

Colony Maintenance

Breeding & HusbandryTo generate this F1 strain, TRAMP transgenic females (Stock No. 003135) are mated with FVB/NJ males (Stock No. 001800).
Diet Information LabDiet® 5K52/5K67

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Pricing for USA, Canada and Mexico shipping destinations             View   International   Pricing
Weeks of AgePrice*GenderGenotypes Provided
Individual Mouse Price $236.40Female or MaleHemizygous for Tg(TRAMP)8247Ng
Pairs /Price*Pair Genotype
$251.30Hemizygous for Tg(TRAMP)8247Ng x FVB/NJ (001800)
*Price(s) in US dollars ($)

Supply Details

Standard SupplyRepository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of ~nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within 48 hours of order placement.
Supply Notes

Pricing for International shipping destinations             View   USA, Canada and Mexico   Pricing
Weeks of AgePrice*GenderGenotypes Provided
Individual Mouse Price $307.40Female or MaleHemizygous for Tg(TRAMP)8247Ng
Pairs /Price*Pair Genotype
$326.70Hemizygous for Tg(TRAMP)8247Ng x FVB/NJ (001800)
*Price(s) in US dollars ($)

Supply Details

Standard SupplyRepository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of ~nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within 48 hours of order placement.
Supply Notes

Control Information

  Control
   Noncarrier
 
  Considerations for Choosing Controls
  USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
  International - Control Pricing Information for Genetically Engineered Mutant Strains.

General Terms and Conditions

View JAX® Mice & Services Conditions of Use.

OncoMouse® requires a license from DuPont, see Licenses for Strains with OncoMouse® Technology.

For additional Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering and Purchasing Information

      Purchasing Information
      JAX® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form


(3.1.1)